2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-119545
    PD159790 179598-53-9 98%
    PD159790 is a selective endothelin-converting enzyme-1 (ECE-1) inhibitor, with an EC50 of 28.1 μM.
    PD159790
  • HY-119557
    Buthiazide 2043-38-1 98.87%
    Buthiazide (Butizide) is a diuretic compound that can be used for high blood pressure research.
    Buthiazide
  • HY-119652
    Toliprolol 2933-94-0 98%
    Toliprolol is a β1/β2-selective β-adrenergic Receptor antagonist. Toliprolol is used in the research of angina pectoris and hypertension.
    Toliprolol
  • HY-119680
    AT-1459 294658-50-7 98%
    AT-1459 is a selective and orally active direct Thrombin inhibitor with a Ki value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases.
    AT-1459
  • HY-119735
    Curcolone 17015-43-9 98%
    Curcolone is a sesquiterpenoid that inhibits collagen-induced or arachidonic acid (AA)-induced platelet aggregation.
    Curcolone
  • HY-119747
    WAY-123223 137941-92-5 98%
    WAY-123223 is an orally active potassium channel (Potassium Channel) blocker. WAY-123223 prolongs the transmembrane action potential duration and cardiac refractory period of canine Purkinje fibers. In canine models, WAY-123223 increases the ventricular fibrillation threshold, restores sinus rhythm from ventricular fibrillation, and exerts antiarrhythmic effects. WAY-123223 can be used in research related to cardiovascular diseases such as arrhythmias.
    WAY-123223
  • HY-119753
    Disobutamide 68284-69-5 98%
    Disobutamide is an antianhythmic agent. Disobutamide slows conduction throughout the atrioventricular conduction system of the isolated perfused rabbit heart.
    Disobutamide
  • HY-119762
    Spizofurone 72492-12-7 98%
    Spizofurone is an anti-ulcer compound with increased gastric mucosal blood flow activity and oral activity. Spizofurone has a similar mechanism of action to PGE2 (HY-101952), Spizofurone is capable of acting through local and systemic pathways and may promote ulcer healing by improving blood supply to the gastric mucosa. Spizofurone can be used to study the development strategy of gastric ulcer.
    Spizofurone
  • HY-119854
    Atiprosine 89303-63-9 98%
    Atiprosine (AY-28228) is an orally effective selective α1-adrenergic receptor antagonist with a pA2 value of 8.11. Atiprosine exhibits antagonistic activity against α2-adrenergic receptors (α1-adrenergic receptor), 5-HT₂ receptors (5-HT₂ receptor), and H₁ receptors (H₁ receptor). The pA2 values for these receptors are 6.04, 6.87, and 7.32 respectively. Atiprosine has antihypertensive and hypotensive effects in rats, dogs, and monkeys. It can be used for research on cardiovascular and mental disorders.
    Atiprosine
  • HY-119860
    Ataprost 83997-19-7 98%
    Ataprost (ONO 41483) is an orally active Carboprostacyclin (HY-112322) analogue. Ataprost exhibits 2.6 times more active than Carboprostacyclin in inhibiting ADP-induced platelet aggregation in vitro. Ataprost has the ability to relieve coronary spasm.
    Ataprost
  • HY-119873
    Celiprolol 56980-93-9 98%
    Celiprolol (REV 5320) is a potent, cardioselective and orally active β1-andrenoceptor r antagonist with partial β2 agonist activity, with Ki values of 0.14-8.3 μM. Celiprolol has antihypertensive and antianginal activity, and can be used for the research of cardiovascular disease such as high blood pressure.
    Celiprolol
  • HY-119890
    Isbogrel 89667-40-3 98%
    Isbogrel (CV-4151) is a potent selective inhibitor of thromboxane A2 synthase. Isbogrel has oral activity and inhibits blood TXA2 generation with an ID50 value of 0.04 mg/kg.
    Isbogrel
  • HY-119995
    Chloropyramine 59-32-5 98%
    Chloropyramine is competitive reversible H1 receptor antagonist. Chloropyramine also has anti-tumour activity in breast cancer. Chloropyramine can be used for the research of allergic conditions, such as conjunctivitis and bronchial asthma.
    Chloropyramine
  • HY-120134
    BMS 183920 153072-33-4 98%
    BMS 183920 is a diacidic and potent angiotensin II receptor antagonist, with a Ki value of 2.9 nM in the rat adrenal cortex binding assay and a KB value of 0.061 nM in the rabbit aorta functional assay. BMS 183920 can be used for research of antihypertensive.
    BMS 183920
  • HY-120141
    L-768673 177954-68-6 98%
    L-768673 is a potent selective IKs blocker with antiarrhythmic effects. L-768673 plays important roles in both atrial and ventricular refractoriness as well as pacemaker function in the dog heart. L-768673 can be used for arrhythmias research.
    L-768673
  • HY-120147
    Ethiazide 1824-58-4 98%
    Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research.
    Ethiazide
  • HY-120148
    SM19712 free acid 194542-49-9 98%
    SM19712 free acid is an orally active, selective endothelin converting enzyme (ECE) inhibitor. SM19712 free acid inhibits conversion of big ET-1 to ET-1. SM19712 free acid attenuates colonic angiogenesis, tissue injury, inflammation, without altering colon shortening or myeloperoxidase levels in mice. SM19712 free acid can be used for the research of inflammatory bowel disease (colitis), ischemic acute renal failure, acute myocardial infarction, and myocardial ischemia/reperfusion injury.
    SM19712 free acid
  • HY-120152
    SLP7111228 1449765-82-5 98%
    SLP7111228 is a selective sphingosine kinase 1 (SphK1) inhibitor and anti-inflammatory agent. SLP7111228 selectively inhibits SphK1 and reduces the production of sphingosine-1-phosphate. SLP7111228 decreases lipopolysaccharide-induced TNFα and IL-1β levels. SLP7111228 alleviates obliterative pulmonary arteriopathy, increases cardiac index and decreases total pulmonary vascular resistance index. SLP7111228 can be used in research related to neuroinflammatory diseases and pulmonary hypertension.
    SLP7111228
  • HY-120168
    CCG 258001 2055990-96-8 98%
    CCG 258001 is a GRK inhibitor with IC50 values of 0.29, 51.8, and 33 µM against GRK2, GRK1, and GRK5, respectively. CCG 258001 inhibits GRK activity in cardiomyocytes and other muscle cells. CCG 258001 is applicable to the research of heart diseases, including heart failure, myocardial hypertrophy, and hypertension.
    CCG 258001
  • HY-120200
    YF-452 1951466-83-3 98%
    YF-452 is a potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2). YF-452 remarkably inhibits the migration, invasion and tube-like structure formation of human umbilical vein endothelial cells (HUVECs) with little toxicity. YF-452 inhibits VEGF-induced phosphorylation of VEGFR2 kinase and the downstream protein kinases including extracellular signal regulated kinase (ERK), focal adhesion kinase (FAK) and Src. YF-452 is a potential antiangiogenic agent candidate for cancer research.
    YF-452
Cat. No. Product Name / Synonyms Application Reactivity